Check and Checkmate: Battling Cancer with Multiplex Immunotherapy.
作者信息
Bell John C
机构信息
Ottawa Hospital Research Institute, 501 Smyth Road, Box 926, Ottawa, ON K1H 8L6, Canada.
出版信息
Mol Ther. 2020 May 6;28(5):1236-1237. doi: 10.1016/j.ymthe.2020.04.013. Epub 2020 Apr 17.
Abstract
摘要
相似文献
1
Check and Checkmate: Battling Cancer with Multiplex Immunotherapy.检查与将死：用多重免疫疗法对抗癌症
Mol Ther. 2020 May 6;28(5):1236-1237. doi: 10.1016/j.ymthe.2020.04.013. Epub 2020 Apr 17.
2
Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.前列腺癌的基因治疗与免疫治疗：基于腺病毒的策略
Acta Oncol. 2005;44(6):610-27. doi: 10.1080/02841860510007477.
3
TGF-β Inhibition and Immunotherapy: Checkmate.TGF-β 抑制与免疫治疗：Checkmate.
Immunity. 2018 Apr 17;48(4):626-628. doi: 10.1016/j.immuni.2018.03.037.
4
Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer.利用体外基因转移改善人类癌症的过继性细胞免疫疗法。
Curr Gene Ther. 2002 Feb;2(1):91-100. doi: 10.2174/1566523023348101.
5
Immunotherapy: Nivolumab keeps HCC in check and opens avenues for checkmate.免疫疗法：纳武单抗可控制肝癌并为战胜癌症开辟途径。
Nat Rev Clin Oncol. 2017 Jul;14(7):392. doi: 10.1038/nrclinonc.2017.70. Epub 2017 May 9.
6
Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes.通过体内直接转移免疫调节基因进行癌症免疫治疗。
Res Immunol. 1998 Sep-Oct;149(7-8):681-4. doi: 10.1016/s0923-2494(99)80038-8.
7
Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo.利用经基因工程改造后能在体内表达白细胞介素-12的树突状细胞（DC）改善肝细胞癌（HCC）的免疫治疗。
Liver Int. 2014 Mar;34(3):447-61. doi: 10.1111/liv.12284. Epub 2013 Sep 2.
8
Genomic and epigenomic perspectives of T-cell exhaustion in cancer.癌症中 T 细胞耗竭的基因组和表观基因组观点。
Brief Funct Genomics. 2019 Mar 22;18(2):113-118. doi: 10.1093/bfgp/ely005.
9
T lymphocyte responses against hepatitis B virus-related hepatocellular carcinoma induced by adenovirus vaccine encoding HBx.腺病毒疫苗编码 HBx 诱导的针对乙型肝炎病毒相关肝细胞癌的 T 淋巴细胞反应。
Int J Mol Med. 2010 Dec;26(6):869-76. doi: 10.3892/ijmm_00000536.
引用本文的文献
1
Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer.口服呼肠孤病毒重塑肠道微生物组并增强结直肠癌的抗肿瘤免疫。
Nat Commun. 2024 Oct 22;15(1):9092. doi: 10.1038/s41467-024-53347-6.
2
Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.嵌合抗原受体 T 细胞疗法在头颈部癌症中的最新进展和未来展望。
Front Immunol. 2023 Jun 29;14:1213716. doi: 10.3389/fimmu.2023.1213716. eCollection 2023.
本文引用的文献
1
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.溶瘤腺病毒武装双特异性 T 细胞结合分子、细胞因子和检查点抑制剂使 CAR T 细胞能够控制异质性肿瘤的生长。
Mol Ther. 2020 May 6;28(5):1251-1262. doi: 10.1016/j.ymthe.2020.02.016. Epub 2020 Feb 24.
2
First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial.首个人体静脉注射塞普雷韦在年轻癌症患者中的临床试验。
Mol Ther. 2019 Nov 6;27(11):1930-1938. doi: 10.1016/j.ymthe.2019.08.020. Epub 2019 Sep 10.
3
Synergistic combination of oncolytic virotherapy with CAR T-cell therapy.溶瘤病毒治疗与 CAR-T 细胞治疗的协同联合。
Prog Mol Biol Transl Sci. 2019;164:217-292. doi: 10.1016/bs.pmbts.2019.06.015. Epub 2019 Jul 19.
4
Recent advances in oncolytic virus-based cancer therapy.溶瘤病毒癌症治疗的最新进展。
Virus Res. 2019 Sep;270:197675. doi: 10.1016/j.virusres.2019.197675. Epub 2019 Jul 25.
5
Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.由于CD-19抗原丢失，CD19导向的嵌合抗原受体T细胞（CAR-T）疗法治疗后大B细胞淋巴瘤快速复发。
Am J Hematol. 2019 Oct;94(10):E273-E275. doi: 10.1002/ajh.25591. Epub 2019 Aug 13.
6
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.溶瘤病毒与细胞疗法联合用于实体瘤治疗。
Front Immunol. 2018 Sep 21;9:2103. doi: 10.3389/fimmu.2018.02103. eCollection 2018.
7
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.嵌合抗原受体 19 治疗急性淋巴细胞白血病中靶抗原丢失的遗传机制。
Nat Med. 2018 Oct;24(10):1504-1506. doi: 10.1038/s41591-018-0146-z. Epub 2018 Oct 1.
8
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.一项 EUS 引导下经皮肿瘤内注射溶瘤病毒 HF10 治疗不可切除局部进展期胰腺癌的 I 期临床试验。
BMC Cancer. 2018 May 25;18(1):596. doi: 10.1186/s12885-018-4453-z.
9
Oncolytic viruses as engineering platforms for combination immunotherapy.溶瘤病毒作为联合免疫疗法的工程平台。
Nat Rev Cancer. 2018 Jul;18(7):419-432. doi: 10.1038/s41568-018-0009-4.
10
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.腺病毒治疗传递细胞因子和检查点抑制剂增强 CAR T 细胞对转移性头颈部癌症的作用。
Mol Ther. 2017 Nov 1;25(11):2440-2451. doi: 10.1016/j.ymthe.2017.09.010. Epub 2017 Sep 14.
Zotero 插件